You are here: Industry Insights > AstraZeneca

News List

Fortress Biotech Announces Agreement with AstraZeneca, Cincinnati Children’s Hospital americanpharmaceuticalreview
January 02, 2020
Fortress Biotech announced Baergic Bio, a newly formed Fortress partner company, has entered into an exclusive worldwide licensing agreement with AstraZeneca for AZD7325 ...
AstraZeneca Divests Rights to Seroquel, Seroquel XR in US and Canada americanpharmaceuticalreview
December 30, 2019
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) ...
AZ, Daiichi grab blockbuster nod for breast cancer med Enhertu fiercepharma
December 27, 2019
For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition.
AstraZeneca Divests Arimidex, Casodex Rights to Juvisé Pharmaceuticals americanpharmaceuticalreview
December 23, 2019
AstraZeneca has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries to Juvisé Pharmaceuticals.
AstraZeneca sells Arimidex and Casodex rights for $181m pharmaceutical-technology
December 23, 2019
AstraZeneca has divested the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) to French pharmaceutical company Juvisé Pharmaceuticals for an upfront payment of $181m.
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia pharmaceutical-business-review
December 20, 2019
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR ...
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial worldpharmanews
December 17, 2019
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of ...
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed worldpharmanews
December 17, 2019
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) ...
AstraZeneca receives Chinese marketing nod for Lynparza biospectrumasia
December 12, 2019
AstraZeneca and MSD have announced that the companies have received marketing authorisation from China’s National Medical Products Administration (NMPA) for Lynparza (olaparib).
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery pharmaceutical-business-review
December 11, 2019
Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page